BioLineRx (BLRX) Amortization of Deferred Charges (2019 - 2025)
BioLineRx (BLRX) recorded quarterly Amortization of Deferred Charges of $702000.0 in Q1 2025, up 2500.0% quarter-over-quarter from $27000.0 in Q4 2024.
BioLineRx (BLRX) Amortization of Deferred Charges (2019 - 2025) Analysis & Trends
BioLineRx's Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $702000.0 for Q1 2025.
- In Q1 2025, Amortization of Deferred Charges changed N/A year-over-year to $702000.0; the TTM figure through Dec 2025 stood at $702000.0 (up 2407.14% YoY), while the FY2025 annual figure was $702000.0, up 4.93% from the prior year.
- Amortization of Deferred Charges was $702000.0 for Q1 2025 at BioLineRx, up from $27000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $702000.0 in Q1 2025 to a low of $27000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 702,000.00 |
| Mar 31, 2025 | 702,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Mar 31, 2019 | 417,000.00 |
| Mar 31, 2019 | 417,000.00 |